Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNX 2127 is a potent BTK Degrader (PROTAC®) (DC50 = 4.5 nM and Dmax = 94%). It comprises a BTK binding moiety joined by a linker to a cereblon (CRBN) ligand. NX 2127 also degrades the transcription factors IKZF1 and IKZF3 (DC50 = 57 and 36 nM, respectively). In vivo, NX 2127 possesses potent target degradation activity across species and demonstrates efficacy in preclinical oncology models. NX 2127 is orally bioavailable.
Sold under license from Nurix Therapeutics
| M. Wt | 719.85 |
| Formula | C39H45N9O5 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 3024312-52-2 |
| PubChem ID | 167282486 |
| InChI Key | XLWJWCMQMBVNSG-LZDHLTRGSA-N |
| Smiles | O=C1C2=CC(N3C[C@H](CC3)CN4CCC(C5=CC=C(C=C5)NC6=NC(N7CCCCC7)=CN=C6C(N)=O)CC4)=CC=C2C(N1C8C(NC(CC8)=O)=O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 35.99 | 50 |
The following data is based on the product molecular weight 719.85. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 2.78 mL | 13.89 mL | 27.78 mL |
| 2.5 mM | 0.56 mL | 2.78 mL | 5.56 mL |
| 5 mM | 0.28 mL | 1.39 mL | 2.78 mL |
| 25 mM | 0.06 mL | 0.28 mL | 0.56 mL |
References are publications that support the biological activity of the product.
Robbins et al (2024) Discovery and preclinical pharmacology of NX-2127, an orally bioavailable Degrader of Bruton's tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies. J.Med.Chem. 67 2321 PMID: 38300987
If you know of a relevant reference for NX 2127, please let us know.
Keywords: NX 2127, NX 2127 supplier, NX2127, NX-2127, potent, BTK, active, degraders, degrades, B-cell, malignancies, Bruton, tyrosine, kinase, PROTAC, PROTACs, targeted, protein, degradation, tpd, orally, bioavailable, in, vivo, Kinase, Degraders, Brutons, Tyrosine, (BTK), 8951, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for NX 2127. Do you know of a great paper that uses NX 2127 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review NX 2127 and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This brochure highlights the tools and services available from Bio-Techne to support your Targeted Protein Degradation and Induced Proximity research, including:
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia